Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant | MicrobiomeTrials← Back to trialsNCT05405387
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-05-03Est. Completion: 2026-12
Enrollment target: 120 participants Locations- Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in
Myeloma Multiple
The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed …
Amiens, FranceEst. completion Jan 1, 2028
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatmen…
Bethesda, United StatesCompleted Jan 1, 2033
Phase 1
Recruiting
Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic MyelodysplasiaMyeloid Leukemia, AcuteNonlymphoblastic Leukemia, AcuteLeukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United StatesEst. completion Apr 30, 2029